Unlocking the Potential: Amylin-Based Therapies as Novel Interventions for Addressing the Nexus of Obesity and Cardiovascular Health

The rising prevalence of obesity and cardiovascular diseases demands innovative therapeutic strategies. This paper explores the potential of amylin-based therapies in addressing the intricate interplay between obesity and cardiovascular health. Amylin, a hormone co-secreted with insulin, regulates glucose metabolism, appetite, and gastric emptying. Despite its established role in diabetes management, recent research highlights its promise in addressing obesity. Pramlintide, a synthetic amylin analog, emerges as a promising intervention for obesity, overcoming limitations of current treatments. Cardiovascular diseases, closely linked to obesity, prompt exploration of amylin's potential cardiovascular benefits. The study examines vasodilatory effects, anti-inflammatory properties, and anti-atherosclerotic effects associated with amylin. Amylin-based therapies, including pramlintide and the investigational drug AM833 (cagrilintide), are scrutinized for their impact on blood pressure, lipid profiles, and cardiovascular markers. Beyond weight loss, the study explores changes in body composition, insulin sensitivity, and lipid metabolism. The safety profile of amylin analogs, particularly pramlintide, is discussed, emphasizing their generally well-tolerated nature with manageable gastrointestinal side effects. In conclusion, amylin-based therapies present a novel approach to address the complex connections between obesity and cardiovascular diseases. The study highlights their potential in modifying body composition, improving metabolic parameters, and influencing cardiovascular outcomes. As research progresses, amylin-based strategies may offer innovative approaches to enhance metabolic and cardiovascular health, potentially reducing the global burden of cardiovascular diseases.